Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00363142 · ClinicalTrials.gov registry record · Phase 3
A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 211
- Enrollment target
NCT00363142 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 211 participants.
The verdict
NCT00363142, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 211 participants
- Enrollment target
Study Summary
This is a 24-week study to evaluate the efficacy and safety of a once-daily ritonavir-boosted fosamprenavir regimen (1400mg/100mg QD) to a 200mg ritonavir-boosted fosamprenavir regimen administered either twice-daily or once-daily.
Interventions
- DRUG Half-boosted Fosamprenavir
- DRUG Full Boosted Fosamprenavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 211 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00363142
The ClinicalTrials.gov registry entry for NCT00363142 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 211 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Half-boosted Fosamprenavir is the first listed.
NCT00363142 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00363142 about?
NCT00363142 is a clinical study titled "A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects". This is a 24-week study to evaluate the efficacy and safety of a once-daily ritonavir-boosted fosamprenavir regimen (1400mg/100mg QD) to a 200mg ritonavir-boosted fosamprenavir regimen administered either twice-daily or once-daily.
What is the current status of trial NCT00363142?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 211 participants. The study started on 2006-05. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00363142?
The interventions under investigation include: Half-boosted Fosamprenavir (DRUG), Full Boosted Fosamprenavir (DRUG).
Who is sponsoring clinical trial NCT00363142?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.